Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Australian Cancer Tech, Galencia Pharmaceuticals Inc. deal

ACU's U.S. subsidiary Adjuvantys Inc. will acquire Galencia for up to US$5

Read the full 125 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE